The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

Shares of The Bristol-Myers Squibb Company (NYSE: BMY)are attempting to claw their way back into positive territory after the ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...